1 / 60

Genetics of the Hemoglobinopathies & Newborn Screening for the Hemoglobinopathies

Genetics of the Hemoglobinopathies & Newborn Screening for the Hemoglobinopathies. 张咸宁 zhangxianning@zju.edu.cn Tel: 13105819271; 88208367 Office: C303, Teaching Building 2016/03. Required Reading.

derekwilson
Download Presentation

Genetics of the Hemoglobinopathies & Newborn Screening for the Hemoglobinopathies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Genetics of the Hemoglobinopathies & Newborn Screening for the Hemoglobinopathies 张咸宁 zhangxianning@zju.edu.cn Tel:13105819271; 88208367 Office: C303, Teaching Building 2016/03

  2. Required Reading Nussbaum RL, et al. Thompson & Thompson Genetics in Medicine, 8th ed. Elsevier,2016,pp195-214; ● Clinical Case Studies-42. Sickle Cell Disease,44. Thalassemia

  3. Part I. Genetics of the Hemoglobinopathies血红蛋白病

  4. Learning Objectives • To review the normal structure-function relationships of Hb and expression of globin genes • To examine the hemoglobinopathies as disorders of Hb structure, or α- or β-globin gene expression • To explore the influences of compound heterozygosity and modifier genes on hemoglobinopathy phenotypes

  5. Compound heterozygote(复合杂合子):An individual, or a genotype, with two different mutant alleles at the same locus • Compound heterozygote ≠homozygote≠ Double heterozygote

  6. Molecular Disease(分子病) A disease in which there is an abnormality in or a deficiency of a particular molecule, such as hemoglobin in sickle cell anemia 酶蛋白病(enzymopathy):Any of a group of congenital disorders caused by an inherited defect in a single specific enzymethat results in a disruption or abnormality in a specific metabolic pathway

  7. Hemoglobinopathies血红蛋白病 • Disorders of the human hemoglobins • The most common single gene disorders in the world • WHO: 5% of the world’s population are carriers for clinically significant hemoglobinopatihies • Well understood at biochemical and molecular levels

  8. HbA: α2β2 / HbF: α2γ2 • Globular tetramer • MW 64.5 kD • α-Chain • 16p13.3 • Polypeptide length of 141 amino acids • β-Chain • 11p15.4 • Polypeptide length of 146 amino acids

  9. Globin Tertiary Structure

  10. Gene cluster基因簇: A group of adjacent genes that are identical or relatedPseudogene假基因: DNA sequence homologous with a known gene but is non-functional

  11. Developmental Expression of Globin Genes and Globin Switching(发育时珠蛋白基因的表达和珠蛋白的转换)

  12. Globin Gene Developmental Expression and Globin Switching • Classic example of ordered regulation of developmental gene expression • Genes in each cluster arranged in • Same transcriptional orientation • Same sequential order as developmental expression • Equimolar production of α-like and β-like globin chains

  13. The normal human Hbs at different stages of development

  14. Clinic Disease: Influences of Gene Dosage and Developmental Expression • Dosage • 4 - vs. 2 -globin alleles per diploid genome • Therefore, mutations required in 4 -globin alleles compared with 2 -globin alleles for same 100% loss of function • Ontogeny(个体发育) •  expressed before vs.  expressed after birth • Therefore, -chain mutations have prenatal consequences, but -chain mutations are not evidenced even in the immediate postnatal period

  15. Genetic disorders of Hb 1. Structural variant: alter the globin polypeptide without affecting its rate of synthesis 2. Thalassemia: reduced rate of production of one or more globin chains 3. Hereditary persistence of fetal hemoglobin (HPFH. 遗传性胎儿血红蛋白持续症) : a group of clinically benign conditions, impairing the perinatal switch from γ- to β-globin synthesis

  16. There are >400 structural variants

  17. HbS is the first variant to be discovered (1949) Its main reservoir is Central Africa where the carrier rate approximates 20%. (Heterozygous advantage) Approximately 8% of African-Americans will carry one sickle gene.

  18. Heterozygote Advantage • Mutant allele has a high frequency despite reduced fitness in affected individuals OR: • Heterozygote has increased fitness over both homozygous genotypes e.g. Sickle cell anemia.

  19. Thalassemia: An imbalance of globin-chain synthesis • Hb synthesis characterized by the absence or reduced amount of one or more of the globin chains of Hb • α-thalassemia • β-thalassemia

  20. Varius forms of α-Thalassemia

  21. Hb Bart’s (hydrops fetalis水肿胎儿)

  22. Hb Bart’s胎儿水肿综合征最常见于中国和东南亚

  23. β-thalassemia:underproduction of the β-chain. ●β-thal trait (β+/ β orβ0 /β) : .asymptomatic (β+:reduced;β0:absent) ●β-thal intermedia (β+/ β+ ): . moderate anemia ●β-thal major (β0 /β0 orβ+/β0 or β+/ β+ ) : . severe anemia during the first two years of life . hepatosplenomegaly . growth failure . jaundice . thalassemic facies

  24. Thalassemias can arise in the following ways: • One or more of the genes coding for hemoglobin chains is deleted. • 2. A nonsense mutation that produces a shortened chain. • 3. A frameshift mutation that produces a nonfunctional chain. • 4. A mutation may have occurred outside the codingregions.

  25. β-globin gene andβ-thalassemia

  26. Part II. Newborn Screening for the Hemoglobinopathies

  27. Learning Objectives • To review the evolving principles of newborn screening • To examine newborn screening (NBS) for the hemoglobinopathies • To understand the appropriate response to a positive hemoglobinopathy NBS • To appreciate the role of clinical follow-up for the hemoglobinopathies

  28. Population-Based Screening

  29. Genomic Medicine • Principles:“5P” Medicine • Change from current paradigm with emphasis on acute intervention • Will rely on strategies from preventive medicine and public health

  30. Genetic Screening • Population-based approach to identify individuals with certain genotypes known to be • Associated with a genetic disease, or • Predisposition to a genetic disease • Disorder targeted may affect • Individuals being screened, or • Their descendents

  31. Objective of Population Screening • To examine all members of the population designated for screening • Carried out without regard for family history • Should not be confused with testing for affected individuals or carriers within families ascertained because of a positive family history

  32. Genetic Screening • Important public health activity • Will have increasingly significant role with availability of more and better screening tests for • Genetic diseases • Diseases with an identifiable genetic component • Critical strategic hurdle for implementation • Venue in which to capture 100% of target population

  33. Principles of Newborn Screening (NBS)

  34. NBS • Public health governmental programs • Population screening for all neonates • Intervention • Prevents or at least ameliorates consequences of targeted disease • Cost-effective • Controversial • Not simply a test, but a system

  35. Criteria for Effective NBS Programs • Treatment is available. • Early institution of treatment before symptoms become manifest has been shown to reduce or eliminate the severity of the illness. • Routine observation and physical examination will not reveal the disorder in the newborn – a test is required.

  36. Criteria for Effective NBS Programs • A rapid and economical lab test is available that is highly sensitive (no false- negatives) and reasonably specific (few false-positives). • The condition is frequent and serious enough to justify the expense of screening; that is, screening is cost-effective.

  37. Criteria for Effective NBS Programs • The societal infrastructure is in place • To inform the newborn’s parents and physicians of the results of the screening test, • To confirm the test results, and • To institute appropriate treatment and counseling.

  38. Evolving NBS Criteria • Treatment available – Not always • Example: Tandem Mass Spectrometry (MS/MS)串联质谱法 • Analogy: Childhood cancer (75% survival) and protocol-driven iterative improvements • Pre-symptomatic treatment effective – No • Example: For rarer hemoglobinopathies may not have accurate knowledge of natural hx

  39. Evolving NBS Criteria • Clinical ascertainment not effective, so test required – Not always • Example: G6-PD deficiency and kernicterus(核黄疸) • Problem: Clinical ascertainment is never 100% • Rapid and effective lab test available – No • Example: Severe combined immunodeficiency (SCID) • Problems: Limited federal funding for test development until recently, and low cost and margin limit corporate interest

More Related